Zinellu, A.; Zoroddu, S.; Fois, S.; Mellino, S.; Scala, C.; Virdis, E.; Zinellu, E.; Sotgia, S.; Paliogiannis, P.; Mangoni, A.A.;
et al. Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study. Antioxidants 2024, 13, 278.
https://doi.org/10.3390/antiox13030278
AMA Style
Zinellu A, Zoroddu S, Fois S, Mellino S, Scala C, Virdis E, Zinellu E, Sotgia S, Paliogiannis P, Mangoni AA,
et al. Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study. Antioxidants. 2024; 13(3):278.
https://doi.org/10.3390/antiox13030278
Chicago/Turabian Style
Zinellu, Angelo, Stefano Zoroddu, Simona Fois, Sabrina Mellino, Chiara Scala, Erika Virdis, Elisabetta Zinellu, Salvatore Sotgia, Panagiotis Paliogiannis, Arduino A. Mangoni,
and et al. 2024. "Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study" Antioxidants 13, no. 3: 278.
https://doi.org/10.3390/antiox13030278
APA Style
Zinellu, A., Zoroddu, S., Fois, S., Mellino, S., Scala, C., Virdis, E., Zinellu, E., Sotgia, S., Paliogiannis, P., Mangoni, A. A., Carru, C., Pirina, P., & Fois, A. G.
(2024). Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study. Antioxidants, 13(3), 278.
https://doi.org/10.3390/antiox13030278
